echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Sanofi's Sarclisa combination therapy has significant efficacy in the treatment of multiple myeloma

    Sanofi's Sarclisa combination therapy has significant efficacy in the treatment of multiple myeloma

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Sanofi announced the latest results of the Phase 3 IKEMA clinical tri.
    The trial is evaluating the addition of the CD38-targeting antibody Sarclisa (isatuximab) to the proteasome inhibitor Kyprolis (carfilzomib, cardinal) in patients with relapsed multiple myeloma (MM) who have received 1-3 prior anti-myeloma treatmen.
    Efficacy and safety of a combination regimen (Kd) of filzomib) and dexamethaso.
    The median progression-free survival (mPFS) was 12 months (95% CI: 18-21; n=123) in the Kd-treated group and 37 months in the Sarclisa+Kd-treated group (H.
    =58; 95%CI: 28-40; n=17
    This result represents the longest mPFS observed in a clinical study investigating a proteasome inhibitor backbone therapy in second-line treatment of relapsed .
    A PFS analysis based on the US FDA recommendation on censoring rules (applicable to approved US prescribing information) showed mPFS of 28 months in the Kd treatment group and 47 months in the Sarclisa+Kd treatment group (HR= 59; 95% CI: 21 - not computable [NC.
    The median time to next treatment (TTNT) was 25 months (95% CI: 19-33) in the Kd treatment group and 49 months in the Sarclisa+Kd treatment group (HR = 55; 95 %CI:36-N.
    TTNT measures the time interval from the date of randomization to the date of the start of the next treatment, allowing a measure of the treatment benefit peri.
    The safety and tolerability of Sarclisa observed in this analysis was consistent with the safety profile of Sarclisa in other clinical trials, and no new safety signals were observ.
    Sarclisa is a monoclonal antibody drug that targets a specific epitope on the CD38 receptor on multiple myeloma cel.
    Sarclisa launched in 2020 and is currently approved in several countries including the US and EU countri.
    In the field of MM, Sarclisa is nearly 5 years later than the CD38 antibody drug Darzalex (Zhaoke®, daratumumab, daratumumab), which is a competing product from Johnson & Johns.
    Darzalex went public in 2015 and has global sales of $023 billion in 202 By comparison, Sarclisa's sales in 2021 will be just 176 million eur.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.